Blueprint Medicines Corp (NASDAQ:BPMC) has received an average rating of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $84.20.
Several brokerages have recently issued reports on BPMC. Zacks Investment Research upgraded Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a research report on Monday, January 15th. Goldman Sachs Group boosted their price objective on Blueprint Medicines from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Raymond James Financial set a $82.00 target price on Blueprint Medicines and gave the stock a “buy” rating in a research report on Sunday, December 10th. JMP Securities upped their target price on Blueprint Medicines from $88.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 11th. Finally, BidaskClub downgraded Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th.
Blueprint Medicines (NASDAQ BPMC) opened at $75.73 on Tuesday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3,389.88, a P/E ratio of -22.21 and a beta of 1.16. Blueprint Medicines has a 52-week low of $32.43 and a 52-week high of $92.00.
Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. research analysts anticipate that Blueprint Medicines will post -3.75 EPS for the current year.
In other Blueprint Medicines news, Director Daniel Lynch sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $63.38, for a total value of $316,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Marion Dorsch sold 18,334 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $65.45, for a total value of $1,199,960.30. Following the completion of the sale, the insider now owns 18,334 shares of the company’s stock, valued at $1,199,960.30. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its holdings in shares of Blueprint Medicines by 31.5% in the second quarter. Wells Fargo & Company MN now owns 28,827 shares of the biotechnology company’s stock valued at $1,462,000 after buying an additional 6,899 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Blueprint Medicines in the third quarter valued at $6,967,000. California Public Employees Retirement System bought a new position in shares of Blueprint Medicines in the second quarter valued at $314,000. Ameriprise Financial Inc. bought a new position in shares of Blueprint Medicines in the third quarter valued at $3,779,000. Finally, California State Teachers Retirement System increased its holdings in shares of Blueprint Medicines by 43.9% in the second quarter. California State Teachers Retirement System now owns 68,861 shares of the biotechnology company’s stock valued at $3,489,000 after buying an additional 20,999 shares in the last quarter. 83.45% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/blueprint-medicines-corp-bpmc-given-consensus-rating-of-buy-by-analysts.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.